Currently, although there is a lot of interest in the development of small molecule inhibitors of P-gp, to overcome multi-drug resistance (MDR) in cancer chemotherapy, this enthusiasm is curtailed by the fact that majority of previously discovered inhibitors could not succeed in passing FDA approved clinical phase trials. Here, PGP is linked to cancer.